요추간판 탈출증 환자의 전산화 단층 촬영 검사상 다열근 위축에 대한 증례 5례 보고

정민규,이길준,황형주,금동호,Jung, Min-Gyu,Lee, Kil-Joon,Hwang, Hyung-Joo,Keum, Dong-Ho 척추신경추나의학회 2008 척추신경추나의학회지 Vol.3 No.2

Objectives : Lumbar multifidus muscle stabilize lumbar spine. Atrophy of multifidus muscle follows disfunction of low back pain patient's activity and increase the reoccurency of herniation of nucleus purposus surgery. Lumbar herniation of nucleus purposus if common cause of low back pain. We have evaluated the atrophy of multifidus of nucleus purposus. Methods : Five patients were diagnosed as Lumbar herniation of nucleus purposus through the CT imaging. CT imaging were visually analysed to know lumbar multifidus muscle atrophy. Results and Conclusions : Examination of multifidus muscle atrophy should be considered with assessing CT imaging of lumbar spine. It may help for further evaluation and planning the treatment of Lumbar herniation of nucleus purposus patient.

한국 재벌 기업집단의 내부자본시장과 자본조달순위이론

정민규,문승진,김병곤 한국자료분석학회 2023 한국자료분석학회 학술대회자료집 Vol.2023 No.1

First-in-Human Phase 1 Study of a B Cell– and Monocyte-Based Immunotherapeutic Vaccine against HER2-Positive Advanced Gastric Cancer

정민규,이기쁨,김효송,권우선,김현옥,김신영,박명환,김우현,최기영,오태권,강창율,정현철,라선영 대한암학회 2024 Cancer Research and Treatment Vol.56 No.1

Purpose BVAC-B is an autologous B cell– and monocyte-based immunotherapeutic vaccine that contains cells transfected with a recombinant human epidermal growth factor receptor 2 (<i>HER2</i>) gene and loaded with the natural killer T cell ligand alpha-galactosylceramide. Here, we report the first BVAC-B study in patients with HER2-positive advanced gastric cancer.Materials and Methods Patients with advanced gastric cancer refractory to standard treatment with HER2+ immunohistochemistry ≥ 1 were eligible for treatment. Patients were administered low (2.5×10⁷ cells/dose), medium (5.0×10⁷ cells/dose), or high dose (1.0×10⁸ cells/dose) of BVAC-B intravenously four times every 4 weeks. Primary endpoints included safety and maximum tolerated BVAC-B dose. Secondary endpoints included preliminary clinical efficacy and BVAC-B-induced immune responses.Results Eight patients were treated with BVAC-B at low (n=1), medium (n=1), and high doses (n=6). No dose-limiting toxicity was observed, while treatment-related adverse events (TRAEs) were observed in patients treated with medium and high doses. The most common TRAEs were grade 1 (n=2) and grade 2 (n=2) fever. Out of the six patients treated with high-dose BVAC-B, three had stable disease with no response. Interferon gamma, tumor necrosis factor-α, and interleukin-6 increased after BVAC-B treatment in all patients with medium and high dose, and HER2-specific antibody was detected in some patients.Conclusion BVAC-B monotherapy had a safe toxicity profile with limited clinical activity; however, it activated immune cells in heavily pretreated patients with HER2-positive gastric cancer. Earlier treatment with BVAC-B and combination therapy is warranted for evaluation of clinical efficacy. Purpose BVAC-B is an autologous B cell– and monocyte-based immunotherapeutic vaccine that contains cells transfected with a recombinant human epidermal growth factor receptor 2 (HER2) gene and loaded with the natural killer T cell ligand alpha-galactosylceramide. Here, we report the first BVAC-B study in patients with HER2-positive advanced gastric cancer. Materials and Methods Patients with advanced gastric cancer refractory to standard treatment with HER2+ immunohistochemistry ≥ 1 were eligible for treatment. Patients were administered low (2.5×107 cells/dose), medium (5.0×107 cells/dose), or high dose (1.0×108 cells/dose) of BVAC-B intravenously four times every 4 weeks. Primary endpoints included safety and maximum tolerated BVAC-B dose. Secondary endpoints included preliminary clinical efficacy and BVAC-B-induced immune responses. Results Eight patients were treated with BVAC-B at low (n=1), medium (n=1), and high doses (n=6). No dose-limiting toxicity was observed, while treatment-related adverse events (TRAEs) were observed in patients treated with medium and high doses. The most common TRAEs were grade 1 (n=2) and grade 2 (n=2) fever. Out of the six patients treated with high-dose BVAC-B, three had stable disease with no response. Interferon gamma, tumor necrosis factor-α, and interleukin-6 increased after BVAC-B treatment in all patients with medium and high dose, and HER2-specific antibody was detected in some patients. Conclusion BVAC-B monotherapy had a safe toxicity profile with limited clinical activity; however, it activated immune cells in heavily pretreated patients with HER2-positive gastric cancer. Earlier treatment with BVAC-B and combination therapy is warranted for evaluation of clinical efficacy.

EGFR Polymorphism as a Predictor of Clinical Outcome in Advanced Lung Cancer Patients Treated with EGFR-TKI

정민규,이지현,조병철,이철호,박형순,강영애,김세규,장준,김대준,라선영,김주항 연세대학교의과대학 2012 Yonsei medical journal Vol.53 No.6

Purpose: Mutations in the epidermal growth factor receptor (EGFR) have been confirmed as predictors of the efficacy of treatment with EGFR-tyrosine kinase inhibitors (TKIs). We investigated whether polymorphisms of the EGFR gene were associated with clinical outcomes in non-small cell lung cancer (NSCLC) patients treated with EGFR-TKI. Materials and Methods: A polymorphic dinucleotide repeat in intron 1 [CA simple sequence repeat in intron 1(CA-SSR1)] in intron 1 and single nucleotide polymorphisms (SNP-216) in the promoter region of the EGFR gene were evaluated in 71 NSCLC patients by restriction fragment length polymorphism and DNA sequencing. The relationship between genetic polymorphisms and clinical outcomes of treatment with EGFR-TKIs was evaluated. Results:SNP-216G/T polymorphisms were associated with the efficacy of EGFR-TKI. The response rate for the SNP-216G/T tended to be higher than that for G/G (62.5% vs. 27.4%, p=0.057). The SNP-216G/T genotype was also associated with longer progression-free survival compared with the GG genotype (16.7 months vs. 5.1 months, p=0.005). However, the length of CA-SSR1 was not associated with the efficacy of EGFR-TKI. Conclusion: SNP-216G/T polymorphism was a potential predictor of clinical outcomes in NSCLC patients treated with EGFR-TKI.

가족통제기업의 초과지배권과 투자-현금흐름 민감도

정민규,김동욱,김병곤 한국산학기술학회 2023 한국산학기술학회논문지 Vol.24 No.1

본 연구에서는 가족통제기업에 있어 지배주주의 초과지배권이 투자-현금흐름 민감도에 미치는 영향을 분석하였다. 분석을 위한 표본자료는 글로벌 금융위기 이후 기간인 2009년부터 2020년까지 한국거래소 유가증권시장에 상장된총 6,954개의 기업-연도 자료이다. 분석을 위해 횡단면 자료를 시간적으로 연결한 불균형 패널자료를 형성하고, 패널자료회귀분석법을 사용하여 분석하였다. 실증분석 결과를 요약하면 다음과 같다. 가족통제기업에서 현금흐름은 기업투자에 영향을 미치고, 지배주주의 초과지배권은 투자-현금흐름 민감도에 조절효과를 갖는다는 것을 알 수 있었다. 초과지배권이 작은 경우에는 투자-현금흐름 민감도를 완화시키는 효과를 가져 오지만, 초과지배권이 커지면 투자-현금흐름 민감도를 완화시키는 효과가 사라진다는 것을 알 수 있었다. 즉 지배가족의 초과지배권이 커져 지배가족이 외부주주의 부를탈취할 수 있는 가능성이 커지면 가족통제가 투자-현금흐름 민감도를 완화시키는 효과는 사라지는 것으로 이해할 수있었다. 이러한 분석 결과에서, 가족통제기업의 초과지배권은 외부주주의 부를 탈취하고 사적이익을 추구하고자 하는유인에 의해 내부자본의 의존도를 증가시키고 과소투자문제와 과잉투자문제를 유발할 수 있는 것으로 이해되었다. 따라서 가족통제기업의 투명한 지배구조체제 정착을 위해 지배가족의 초과지배권을 통한 사익추구를 통제할 수 있는 제도적장치가 마련될 필요가 있는 것으로 판단된다.

간세포암종의 복강경 및 경피적 초음파 유도하 고주파 열치료: 예비 결과 보고

정민규,이종협,김태석,김현수,조창민,탁원영,권영오,김성국,최용환,정준모 대한간학회 2002 Clinical and Molecular Hepatology(대한간학회지) Vol.8 No.2

Background/Aims: Radiofrequency ablation (RFA) is emerging as a new therapeutic method in the management of hepatocellular carcinoma (HCC). We report the results of 64 patients with a follow-up interval of 3 to 19 months. Method: Sixty-four patients with 82 nodules underwent ultrasound guided RFA. The mean tumor diameter was 2.5±1.0 cm. Laparoscopic ultrasound guided RFA was performed in 38 cases, and percutaneous ultrasound guided RFA in 26 cases. The therapeutic efficacy was evaluated by means of three-phase dynamic abdominal computed tomography (CT) performed within at least one week after ablating. The recurrence was evaluated after treatment by means of abdominal CT and alpha fetoprotein every 3 months. We calculated cumulative recurrence rates, survival rates of patients, and found out complication of RFA. Results: Cumulative recurrence rates in 3, 6, 12 months after RFA was 8.8%, 15.8%, 25.9%. 12 cases were recurred during follow-up. Among them, intrahepatic recurrences were noted in 11 cases, local recurrences in 3 cases. Cumulative survival curves indicated that survival rate was 95% at the third month, 94% at the sixth month, 81% at the twelfth month. After RFA, the alpha fetoprotein level was decreased significantly after 1 month (p<0.05), and serum transaminase levels were transiently elevated (p<0.01) but returned to normal within one week. Complications of RFA were not serious, and resolved spontaneously. Conclusion: RFA can be considered a useful new treatment for HCC. Laparoscopic RFA is a useful procedure for the treatment of HCC regardless of its location.(Korean J Hepatol 2002;8:209-217) 목적 : 고주파 열치료는 최근 간세포암종의 새로운 치료법의 하나로 인정되고 있다. 최소 3개월 이상 19개월까지 추적 관찰된 64 명을 대상으로 하여 그 효용성에 대해 조사하였다. 대상과 방법 : 간세포암종으로 진단된 환자 64명을 대상으로 82개의 종괴에 대하여 초음파 유도하에 고주파 열치료를 시행하였다. 종괴의 평균 크기는 2.5±1.0cm이였다. 종괴 부위로의 접근 방법으로 복강경 유도하 시술을 한 경우가 38예였으며, 경피적으로 천자를 시행한 경우는 26예였다. 치료 성공 여부를 알아보기 위해 고주파 열치료 후 3일에서 1주일 사이에 CT을 시행하였다. 고주파 열치료 후 매 3개월마다 CT와 혈청 AFP로 재발 여부를 확인하였다. 누적 재발률과 생존률을 3, 6, 12개월째 알아보고, 고주파 열치료의 합병증에 대하여 알아보고자 하였다. 결과 : 64명의 대상 환자들의 3개월, 6개월, 12개월이 되는 시점에서의 누적 재발율은 각각 8.8%, 15.8%, 25.9%였다. 전체 추적 기간중 재발은 모두 12예였으며, 이 중 11예에서 간내 재발한 소견을 보였고, 이중 국소 재발은 3예였다. 또한, 3, 6, 12개월이 되는 시점에서의 생존률은 각각 96.4%, 94.2%, 80.8%였다. 혈청 AFP 치는 시술전에 비하여 시술후 1개월째에 감소되는 소견을 보였다 (p<0.05). 고주파 열치료 후 AST, ALT가 일시적으로 증가하였으나 (p<0.01), 1주일이내에 이전 수치로 회복되었다. 고주파 열치료에 따른 합병증은 심각하지 않았으며, 대부분 자연적으로 치유되었다. 결론 : 고주파 열치료는 간세포암종의 국소 치료에 효과적이고 안전한 방법으로 생각된다. 특히 복강경을 이용하면, 종괴의 위치에 관계없이 간세포암종의 치료에 이용될 수 있을 것으로 생각된다.색인단어 : 고주파 열치료, 간세포암종

다중 접근 네트워크에서의 새로운 멀티캐스트 기법

정민규,김용민,김종권 한국통신학회 1994 韓國通信學會論文誌 Vol.19 No.9

화상 회의시스템이나 컴퓨터 지원 협동 작업 시스템과 같은 고도 정보 통신 서비스는 멀티-파티 통신 기능이 필요하다. 따라서 이러한 서비스들을 제공하기 위해서 미래의 네트워크는 유연하고 효율적인 멀티-파티 통신을 지원할 수 있어야 한다. 본 논문에서는 물리적 망 계층과 논리적인 네트워크 계층에서 패킷을 여과하는 새로운 개념의 멀티캐스트 기법을 제안하였다. 이 새로운 방법은 멀티캐스트 통신의 주요 오버헤드인 패킷 전송 오버헤드와 패킷 처리 오버헤드를 줄일 수 있다는 가능성을 가지고 있다. 새로운 방법을 실제 패킷 방송 방식의 네트워크에 응용하기 위해, 여러 개의 목적지 호스트를 포함할 수 잇는 적당한 그룹 주소 집합을 찾는 그룹 매칭 알고리즘을 개발하였고, 두 개의 예를 들어 새로운 멀티캐스트 기법과 알고리즘을 설명하였다. Broadband ISDN will support advanced communication services such as multimedia conference, VOD and electronic news service. Because many of these advanced services require multimedia data delivery, future communication networks must have flexible and efficient multiparty communications capabilities. In this paper we propose a new multicasting method which uses packer filtering capabilities both in a physical network and in a logical network layers. This new scheme has potential to reduce the transmission and packet processing overheads of multicast communications. For the new multicasting method, we develop a group matching algorithm which finds a suitable set of groups that covers multiple target hosts. We show the application of the multicasting method and the group matching algorithm with two simple examoles.

밀리미터파 수동 이미정 시스템 연구 III

정민규,채연식,김순구,윤진섭,미즈노 코지,이진구,Jung, Min-Kyoo,Chae, Yeon-Sik,Kim, Soon-Koo,Yoo, Jin-Seob,Koji, Mizuno,Rhee, Jin-Koo 대한전자공학회 2007 電子工學會論文誌-TC (Telecommunications) Vol.44 No.3

이차원 이미징 배열소자를 갖는 밀리미터파 수동 이미징 시스템을 제작하였다. 이 이미징 시스템을 제작하기 위하여 하나의 기판에 페르미테이퍼 슬롯 안테나. 발룬, 저잡음 증폭기 검파기가 집적되어 있는 이미징 배열 소자를 개발하였다. 또한 $2\times2$의 이미징 배열소자가 배열된 시스템으로 사람의 밀리미터파 수동 이미지를 얻었다. 현재 실시간 35GHz 밀리미터파 수동 이미지 시스템 개발을 위한 이차원 배열 소자를 개발 중에 있다. 제작된 이차원 이미징 배열소자를 갖는 밀리미터파 수동 이미징 시스템을 바탕으로 밀리미터파 실시간 영상을 취득할 수 있는 밀리미터파 수동 이미징 시스템의 실현을 기대할 수 있게 되었다. We have developed a passive millimeter wave (PMMW) imaging system with two-dimensional imaging arrays. For the imaging system we achieved single-substrate imaging-array element which include all necessary component such as Fermi tapered slot antenna (TSA), a balun, LNA's and a detector circuit on it. Two-dimensional arrays for real-time imaging at the 35 GHz band are currently under development. We will be able to make an advanced PMMW image system based on our system with the $2\times2$ imaging array in the near future.

Prognostic and Predictive Value of Carcinoembryonic Antigen and Cytokeratin-19 Fragments Levels in Advanced Non-Small Cell Lung Cancer Patients Treated with Gefitinib or Erlotinib

정민규,조병철,김세현,홍수정,강영애,김세규,장준,라선영,김주항,김대준 연세대학교의과대학 2012 Yonsei medical journal Vol.53 No.5

Purpose: The prognostic and predictive value of pretreatment serum levels of carcinoembryonic antigen (CEA) and cytokeratin-19 fragments (CYFRA 21-1) were assessed in advanced non-small cell lung cancer (NSCLC) patients treated with gefitinib or erlotinib. Materials and Methods: Pretreatment CEA and CYFRA 21-1 were measured in 123 advanced NSCLC patients receiving gefitinib or erlotinib. High CEA levels (h-CEA) were significantly associated with females, patients with adenocarcinoma, and non-smokers. Results: Low CYFRA 21-1 levels (l-CYFRA) were significantly associated with a good performance status (ECOG PS 0-1). The overall response rate (RR) was 27.6%, and higher RR was associated with adenocarcinoma, h-CEA, and epidermal growth factor receptor (EGFR) mutation. Patients with h-CEA had significantly longer progression-free survival (PFS) (p=0.021). Patients with l-CYFRA had significantly longer PFS and overall survival (p=0.006 and p<0.001, respectively). Of note, h-CEA and l-CYFRA had good prognosis in patients with unknown EGFR mutation status or patients with squamous cell carcinoma (p=0.021 and p=0.015, respectively). A good ECOG PS (HR=0.45, p=0.017), h-CEA (HR=0.41, p=0.007), l-CYFRA 21-1 (HR=0.52, p=0.025), and an EGFR mutation (HR=0.22, p<0.001) were independently predictive of a longer PFS. Conclusion: h-CEA and l-CYFRA 21-1 may be prognostic and predictive serum markers for higher response and longer survival in patients with advanced NSCLC receiving gefitinib or erlotinib, especially in patients with unknown EGFR mutation status or patients with squamous cell carcinoma.

Pharmacogenomic Assessment of Outcomes of Pemetrexed-Treated Patients with Adenocarcinoma of the Lung

정민규,이철호,박형순,이지현,강영애,김세규,장준,김대준,라선영,김주항,조병철 연세대학교의과대학 2013 Yonsei medical journal Vol.54 No.4

Purpose: The main objective of this study was to evaluate the association between polymorphisms of the target genes of pemetrexed and clinical outcomes in non-small cell lung cancer (NSCLC) patients treated with pemetrexed. Materials and Methods: We assessed polymorphisms at 8 sites in 4 genes [thymidylate synthase (TS), dihydrofolate reductase (DHFR; 1610, 680, 317, intron 1), methylenetetrahydrofolate reductase (MTHFR; 677, 1298), glycinamide ribonucleotide formyl transferase (GARFT; 2255)] associated with pemetrexed metabolism using polymerase chain reaction, gene scanning, and restriction fragment length polymorphism analysis in 90 patients with adenocarcinoma of the lung. Results: Survival was significantly longer with pemetrexed in patients with TS 3RGCC/3RGCC or 3RGGC/3RGGC compared with the other groups (PFS; 5.2 months vs. 3.7 months, p=0.03: OS; 31.8 months vs. 18.5 months, p=0.001). Patients with DHFR 680CC experienced fatigue more frequently (50% vs. 8.6%, p=0.008). Polymorphisms of MTHFR and GARFT were not significantly associated with clinical outcomes of pemetrexed. Conclusion: The TS genotype was associated with survival and one DHFR polymorphism was associated with fatigue in NSCLC patients treated with pemetrexed. Further large prospective studies are required to identify other biomarkers that affect patients being treated with pemetrexed for adenocarcinoma of the lung.